- Home
- NOTE vs ACRV Comparison
NOTE vs ACRV Comparison
Compare NOTE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTE
- ACRV
- Stock Information
- Founded
- NOTE 2013
- ACRV 2018
- Country
- NOTE United States
- ACRV United States
- Employees
- NOTE N/A
- ACRV N/A
- Industry
- NOTE EDP Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- NOTE Technology
- ACRV Health Care
- Exchange
- NOTE Nasdaq
- ACRV Nasdaq
- Market Cap
- NOTE 169.3M
- ACRV 170.3M
- IPO Year
- NOTE N/A
- ACRV 2022
- Fundamental
- Price
- NOTE $1.27
- ACRV $5.78
- Analyst Decision
- NOTE Strong Buy
- ACRV Strong Buy
- Analyst Count
- NOTE 6
- ACRV 5
- Target Price
- NOTE $3.30
- ACRV $22.40
- AVG Volume (30 Days)
- NOTE 4.0M
- ACRV 52.8K
- Earning Date
- NOTE 03-11-2025
- ACRV 11-13-2024
- Dividend Yield
- NOTE N/A
- ACRV N/A
- EPS Growth
- NOTE N/A
- ACRV N/A
- EPS
- NOTE N/A
- ACRV N/A
- Revenue
- NOTE $125,062,000.00
- ACRV N/A
- Revenue This Year
- NOTE N/A
- ACRV N/A
- Revenue Next Year
- NOTE $4.01
- ACRV N/A
- P/E Ratio
- NOTE N/A
- ACRV N/A
- Revenue Growth
- NOTE N/A
- ACRV N/A
- 52 Week Low
- NOTE $0.75
- ACRV $3.19
- 52 Week High
- NOTE $2.27
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- NOTE 55.08
- ACRV 43.36
- Support Level
- NOTE $0.98
- ACRV $5.36
- Resistance Level
- NOTE $1.37
- ACRV $6.00
- Average True Range (ATR)
- NOTE 0.15
- ACRV 0.54
- MACD
- NOTE -0.00
- ACRV -0.02
- Stochastic Oscillator
- NOTE 53.70
- ACRV 24.73
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of global policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With expert analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.